The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients

作     者：Xiaoyang Zhai Jian Zhang Yaru Tian Ji Li Wang Jing Hongbo Guo Hui Zhu Xiaoyang Zhai;Jian Zhang;Yaru Tian;Ji Li;Wang Jing;Hongbo Guo;Hui Zhu

作者机构：Department of Radiation OncologyShandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinan 250117China Department of Thoracic SurgeryShandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinan 250117China Department of Radiation OncologyShandong Cancer Hospital and Institute affiliated with Shandong UniversityJinan 250012China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2020年第17卷第3期

页      面：599-611页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by a grant from the Wu Jieping Medical Foundation(Grant No.320675018288). 

主　　题：Immune checkpoint inhibitor non-small-cell lung cancer pneumonitis risk factors 

摘      要：Immune checkpoint inhibitors(ICIs)are new and promising therapeutic agents for non-small cell lung cancer(NSCLC).However,along with demonstrating remarkable efficacy,ICIs can also trigger immune-related adverse events.Checkpoint inhibitor pneumonitis(CIP)has been reported to have a morbidity rate of 3%to 5%and a mortality rate of 10%to 17%.Moreover,the incidence of CIP in NSCLC is higher than that in other tumor types,reaching 7%to 13%.With the increased use of ICIs in NSCLC,CIP has drawn extensive attention from oncologists and cancer researchers.Identifying high risk factors for CIP and the potential mechanism of CIP are key points in preventing and monitoring serious adverse events.In this review,the results of our analysis and summary of previous studies suggested that the risk factors for CIP may include previous lung disease,prior thoracic irradiation,and combinations with other drugs.Our review also explored potential mechanisms closely related toCIP,including increasedT cell activity against associated antigens in tumor and normal tissues,preexisting autoantibodies,and inflammatory cytokines.